齐艳飞,单可人,徐鹰,赵明祥,刘芳,李光荣,张婷,李毅,官志忠,任锡麟
QI Yan-fei 1; SHAN Ke-ren 1; XU Ying 1; ZHAO Ming-xiang 2; LIU Fang 2; LI Guang-rong 2; ZHANG Ting 1; LI Yi 1; GUAN Zhi-zhong 1; REN Xi-lin 1 (1. Molecular Biological Key Laboratory of Guiyang Medical College;

• 1:贵阳医学院分子生物学重点实验室
• 2:贵阳医学院分子生物学重点实验室
• 3:贵阳医学院分子生物学重点实验室
• 4:贵阳医学院附院神经科

摘要(Abstract)：

目的:探讨散发性阿尔茨海默病(SporadicAlzheimerdisease简称SAD)和中枢型尼古丁胆碱能受体α4亚单位(CHRNA4)外显子五基因多态性的关联关系。方法:用聚合酶链式反应-变性梯度凝胶电泳(PCR-DGGE)和DNA测序技术分析23例SAD病人及30例正常人的CHRNA4基因的外显子五序列。结果:在CHR-NA4的外显子五上发现3个多态性位点:G1478A(χ2=0.24,P>0.05);A1374G(χ2=0.24,P>0.05);T1344C(χ2=0.24,P>0.05)。由统计学结果得出该3个多态位点在病例组与对照组之间没有差异。结论:在CHR-NA4外显子五上发现的3个多态性位点与阿尔茨海默病(AD)的发病可能不存在相关关系。
Objective: To investigate the association of genetic polymorphisms of CHRNA4 with sporadic Alzheimer disease. Methods: In 23 sporadic Alzheimer disease (SAD) patients and 30 normal people, exon5 of CHRNA4 was screened with PCR-DGGE technique and sequencing. Results: Three genetic polymrphisms were found in SAD patients and control group:G1487A(χ 2=0.24, P >0.05 );A1374G(χ 2=0.24, P >0.05);T1344C(χ 2=0.24, P >0.05). Conclusions: These three genetic polymorphisms may not be associated with pathogenesis of SAD, since there is no statistical difference between SAD group and control group.

关键词(KeyWords)： 阿尔茨海默病;受体,胆碱能;聚合酶链反应;电泳,琼脂凝胶;中枢型尼古丁胆碱能受体α4亚单位
Alzheimer disease; receptors,cholinergic; polymerase chain reaction; electrophoresis, agar gel; nicotinic acetylcholine receptor α4 subunit

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金资助项目(30340080);; 贵州省科学技术厅国际合作资助项目(200211008)

作者(Authors): 齐艳飞,单可人,徐鹰,赵明祥,刘芳,李光荣,张婷,李毅,官志忠,任锡麟
QI Yan-fei 1; SHAN Ke-ren 1; XU Ying 1; ZHAO Ming-xiang 2; LIU Fang 2; LI Guang-rong 2; ZHANG Ting 1; LI Yi 1; GUAN Zhi-zhong 1; REN Xi-lin 1 (1. Molecular Biological Key Laboratory of Guiyang Medical College;

DOI: 10.19367/j.cnki.1000-2707.2005.03.002

参考文献(References)：

• [1]D J Selkoe.Alzheimer’disease:gene,proteins and therapy[J].Physiol Rev,2001,81:741-766.
• [2]Felician O,Sandson TA.The neurobiology and pharmaco-therapy of Azheimer’s disease[J].J Neuropsychiatry Clin Neurosci,1999,11:19-31.
• [3]Lisa R Fodero,David H.Small:Cholinergic Abnormalities in Alzheimer’s Disease:Are There New Targets for Drug Development[J].Drug Development Research,2002,56:369-379.
• [4]张明园.精神科评定量表手表[M].长沙:湖南科学技术出版社,1993.184-186.
• [5]American Psychiatric Association.DSM-IV:diagnostic and statistical manual of mental disorders[M].4th ed.Washington:American Psychiatric Association,1994.92-94.
• [6]McKhann G,Drachman D,Folstein M,et al.Cllinical diag-nosis of Alzheimer’s disease:report of thd NINCDS-ADRDA Work Group under the auspices of Department of Healthe and Human Services Task Force on Alzheimer’sDisease[J].Neurology,34(84)939-944.
• [7]Marutle A,Warpman U,Bognanovic N,et al.Regional dis-tribution of subtypes of micotinic receptors in human brain and effect of aging studied by epibatidine[J].Brain Res,1998,801:743-149.
• [8]Schr der H,Van de Vos RA,Jansen EN,et al.Gene ex-pression of the nictinic acetylcholine receptorα4su unit in the frontal cortex of Parkinson’s disease patients[J].Neu-rosci Lett,1995,187:173-176.
• [9]U Warpman,A Nordberg.Epibatidine and ABT418erveal selective losses of alpha4beta2nicotinic receptors in Alzheimer brains[J].NeuroReport,1996,6:2419-2423.
• [10]A Wevers,L Monteggia,S Nowacki,et al.Expression of nicotinic acetylcholine receptor subunits in teh cerebral cortex in Alzheimer’s disease:histotopographical correla-tion correlation with amyloid plaques and hyperhposhoo-rylated-tau protein[J].Eur J Neurosci,1999,11:2551-2565.
• [11]Z-Z.Guan,X Zhang,R Ravid A,et al.Kecreased pro-tein levels of nicotinic receptor subunits in the hippocam-pus and temporal cortex of patients with Alzheimer’s dis-ease[J].J Neurochem,2000,74:237-243.
• [12]Martin-Ruiz,J ACourt,E Molnan,et al.Alpha4but notal-pha3and alpha7nicotinic acetylcholine receptor subunits are lost from thd temporal cortex in Alzheimer’s disease[J].J Neurochem,1999,73:1635-1640.
• [13]H Togi,K Utsugisawa,M Yoshimura,et al.Age-related changes in nicotinic acetylcholine receptor subunitsα4andβ2messenger RNA expression in postmortem human frontal cortex and hippocampus[J].Neurosci Lett,1998,245:139-142.
• [14]Martin-Ruiz C M,Court J A.Association of novel and es-tablished polymrphism in neuronal nicotinic acetylcholine receptors with sporadic Alzheime’s disease[J].Journal of Alzheimer’s Disease,2002,4:71-76.
• [15]Cout J.Nicotinic receptor abnormalities in Akzheimer’s Disease[J].Biological Psychiatry,2001,49:175-84.
• [16]TKihara,S Shimohama,HSawada,et al.Nicotinic recep-tor stimulation protects neurons against beta-anyloid toxic-ity[J].Ann Neurol,1997,42:159-163.
• [17]TKihara,S Shimohama,M Urushitani,et al.Stimulation of alpha4beta2nicotinic acetylcholine receptors inhibits beta-amyloid toxicity[J].Brain Res,1998,792:331-334.
• [18]Steinlein O,Weiland S,Stoodt J,et al.Exon-Intron Struc-ture of the Human Neuronal Nicotinic Acetylcholine Re-ceotorα4Subunit(CHRNA4)[J].Genomics,1996,32:289-294.
• [19]O K.Steinlein,J Stoodt,R A I de Vos,et al.Mutation screening of the CHRNA4and CHRNB2nicotinic cholin-ergic receptor genes in Aizheimer’s disease[J].Neuro-Report1999,10:2919-2922.
• [20]Kawamata J.Shimohama S.Association of novel and estab-lished polymrphism in neuronal nicotinic acetylcholine re-ceptors with sporadic Alzheiner’s disease[J].Journal of Alzheimer’s Disease,2002,4:71-76.
• [21]Kim H,Flanagin BA.The mouse Chrna4A529T ploymor-phism alters the ratio of high to low affinity alopha4beta2nAChRs[J].Neuriopharmacology,2003,45:345-354.
• [22]Lynnette J Cook,Luk WHo.Candidate gene association stud-ies of theα4(CHRNA4)andβ2(CHRNB2)neuronal nicotin-ic acetylcholine receptor subunit genes in Alzheimer’s dis-ease[J].Neuroscience Letters,2004,358:142-146.

文章评论(Comment)：